Product Description
Mechanisms of Action: MAPK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Myocardial Ischemia|Coronary Artery Disease|Coronary Disease|Acute Respiratory Distress Syndrome|Neuropathic Pain|Neuralgia|Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Chronic Obstructive Pulmonary Disease
Phase 1: Chronic Obstructive Pulmonary Disease|Inflammation|Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00564746 |
Type 3C | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2007-10-26 |
2019-03-22 |
Treatments |
|
NCT00380133 |
IPI100477 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2006-04-01 |
2019-03-21 |
Treatments |
|
NCT00419809 |
RA1101607 | P1 |
Completed |
Arthritis, Rheumatoid |
2005-12-01 |
2019-03-21 |
Treatments |
|
NCT00439881 |
RA1107570 | P1 |
Completed |
Inflammation|Arthritis, Rheumatoid |
None |
2019-03-21 |
Treatments |
|
NCT00996840 |
NCT00996840 | P2 |
Completed |
Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Acute Respiratory Distress Syndrome |
2013-02-09 |
2019-03-19 |
Treatments |
|
NCT00390845 |
MKN106762 | P2 |
Completed |
Neuropathic Pain|Neuralgia |
2008-08-11 |
2019-03-21 |
Treatments |
|
2006-001072-21 |
2006-001072-21 | P2 |
Completed |
Neuropathic Pain |
2008-08-11 |
2022-03-12 |
Treatments |
|
2005-002219-26 |
2005-002219-26 | P2 |
Completed |
Arthritis, Rheumatoid |
2006-10-18 |
2022-03-12 |
Treatments |
|
NCT00320450 |
RA1100849 | P2 |
Completed |
Arthritis, Rheumatoid |
2006-10-01 |
2019-03-21 |
Treatments |
|
NCT00134693 |
RA1104046 | P2 |
Completed |
Arthritis, Rheumatoid |
2006-08-03 |
2019-03-21 |
Treatments |
|
2004-005115-29 |
2004-005115-29 | P2 |
Completed |
Arthritis, Rheumatoid |
2006-08-03 |
2022-03-12 |
Treatments |
|
2005-004285-16 |
2005-004285-16 | P2 |
Completed |
Coronary Disease |
2006-07-11 |
2022-03-12 |
Treatments |
|
2004-002769-18 |
2004-002769-18 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2006-03-02 |
2022-03-12 |
Treatments |
|
NCT00291902 |
PMK103351 | P2 |
Completed |
Myocardial Ischemia|Coronary Artery Disease |
None |
2019-03-21 |
Treatments |
|
NCT00144859 |
MKC101614 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/01/2020 |
PubMed |
Emerging pharmacological therapies for ARDS: COVID-19 and beyond. |